Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

ODYSSEY

ODYSSEY Outcomes: alirocumab reduces cardiovascular events and death after acute coronary syndrome

ODYSSEY Outcomes: alirocumab reduces cardiovascular events and death after acute coronary syndrome

Top-line results presented at the 67th Scientific Sessions of the American College of Cardiology, Orlando, Florida provide definitive evidence for targeting PCSK9 inhibition to patients at highest risk with persistently elevated LDL cholesterol levels despite intensive statin therapy. Although further data are needed, this is…

read more »
PlayESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

ESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

This Task Force from the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) has considered new evidence from cardiovascular outcomes studies with evolocumab (FOURIER) and bococizumab (now terminated), new analyses and genetic studies.t Taking account of the cost of these agents, the Task…

read more »
ADA 2017: Alirocumab shows benefit in diabetes patients

ADA 2017: Alirocumab shows benefit in diabetes patients

Data from the ODYSSEY trials, including a pooled analysis of nearly 1,000 patients, reported at the American Diabetes Association (ADA) 2017 Scientific Sessions showed that alirocumab was effective in type 1 and 2 diabetes patients, including those with mixed dyslipidaemia, with no impact on HbA1c….

read more »
ODYSSEY DM – Insulin

ODYSSEY DM – Insulin

Trial Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM – Insulin) ClinicalTrials.gov Identifier: NCT02585778 Aim To demonstrate the superiority…

read more »
ODYSSEY-DM-INSULIN: alirocumab in type 1 and 2 diabetes

ODYSSEY-DM-INSULIN: alirocumab in type 1 and 2 diabetes

This phase III study is addressing unanswered questions relating to the efficacy of the PCSK9 inhibition in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk. Briefly, this randomized, double-blind, placebo-controlled, multicentre study plans to enrol 400 patients with type 2…

read more »
ESC Poster news: More reassurance on alirocumab safety at very low LDL cholesterol

ESC Poster news: More reassurance on alirocumab safety at very low LDL cholesterol

30th August 2016, Rome, Italy In an updated safety analysis for alirocumab treatment for up to 104 weeks, there was no evidence of any safety issues affecting neurological or neurocognitive function with alirocumab (1). Data were pooled from 14 Phase II and III trials, comprising…

read more »
ESC Poster news: Alirocumab effective in patients with multiple manifestations of cardiovascular disease

ESC Poster news: Alirocumab effective in patients with multiple manifestations of cardiovascular disease

30th August 2016, Rome, Italy Alirocumab, was effective and well tolerated in patients with multiple manifestations of cardiovascular disease receiving statins with or without other lipid lowering therapy, according to a post hoc analysis of the ODYSSEY trials (1). The investigators evaluated data from patients…

read more »
PCSK9 inhibition reduces the need for lipoprotein apheresis in severe heterozygous familial hypercholesterolaemia patients

PCSK9 inhibition reduces the need for lipoprotein apheresis in severe heterozygous familial hypercholesterolaemia patients

ESC Congress, Rome, 29 August 2016 Results from this Monday Hotline of the ODYSSEY ESCAPE study show that treatment with the PCSK9 monoclonal antibody alirocumab reduces the frequency of lipoprotein apheresis in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) requiring this therapy. At…

read more »
ODYSSEY trials analysis: Alirocumab 75 mg 2-weekly adequate in most patients

ODYSSEY trials analysis: Alirocumab 75 mg 2-weekly adequate in most patients

One question from the phase III trials with the PCSK9 monoclonal antibody alirocumab is how many high cardiovascular risk patients require uptitration. Results from an analysis of more than 1200 patients included in 6 Phase III trials from the ODYSSEY programme show that most attained…

read more »
PlayODYSSEY 78 week HeFH data: Clinical perspectives

ODYSSEY 78 week HeFH data: Clinical perspectives

PCSK9 monoclonal antibody therapy has been shown to be highly efficacious in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol). However, as patients will require treatment in the long-term, efficacy and safety data are needed. The recent publication of 78 week data from the…

read more »
ODYSSEY 78-week data in heterozygous FH: PCSK9 FORUM Expert view

ODYSSEY 78-week data in heterozygous FH: PCSK9 FORUM Expert view

ESC Congress 2015, 1 September 2015 Familial hypercholesterolaemia (FH, inherited high cholesterol) represents one of the key priorities for PCSK9 monoclonal antibody therapy. This analysis from the ODYSSEY clinical programme with alirocumab, which has the largest group of heterozygous FH patients studied to date, establishes…

read more »